Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

545.50 -24.14 (-4.24%)
Streaming Delayed Price Updated: 12:14 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Is It Time to Take Some Gains in Novo Nordisk Stock? Not So Fast.
Novo Nordisk stock has been on a tear, but the company's latest financial report suggests it may just be getting started. 
Via The Motley Fool
Want to Get Rich? 3 Game-Changing Growth Stocks to Buy Right Now
Look to these growth stocks to buy to provide huge growth moving forward as they each have strong catalysts and bullish long-term outlooks. 
Via InvestorPlace
Is It Too Late to Buy Eli Lilly Stock?
Shares of the pharmaceutical company have crushed the market so far this year. 
Via The Motley Fool
Is Alexandria Real Estate Equities a Buy?
Great company, attractive valuation, lousy sector. 
Via The Motley Fool
Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government
AstraZeneca Plc (NASDAQ: AZN) announced its legal challenge against the U.S. 
Via Benzinga
This Is What Whales Are Betting On Eli Lilly
Via Benzinga
Check Out What Whales Are Doing With LLY
Via Benzinga
Live Off The Fat Of The Land With These Two Stocks
These two pharmaceutical companies will turn into massive money-making machines. 
Via Talk Markets
How Novo Nordisk, A Top 1% Stock, Just Hit Another Bull's-eye In Obesity Treatment
The company tested its drug, Wegovy, in patients with a common form of heart failure. 
Via Investor's Business Daily
This New Development Is Helping to Send Eli Lilly and Novo Nordisk Stocks Soaring
Some of their winning medicines could soon compete in new markets. 
Via The Motley Fool
7 A-Rated Growth Stocks to Grab Up Now
Investing in A-rated growth stocks is one of the best tools you have to build your portfolio and set it up for long-time growth. 
Via InvestorPlace
Got $5,000? Invest in These 2 Unstoppable Growth Stocks.
Both of these companies are coming off strong quarters, with more growth on the horizon. 
Via The Motley Fool
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It
NASH is a surprisingly common ailment, and the first treatments are on the way. 
Via The Motley Fool
Eli Lilly Reveals Topline Data From Pivotal Study In Rare Type Of Thyroid Cancer
Eli Lilly And Co (NYSE: LLY) released topline results from the LIBRETTO-531 study evaluating Retevmo versus the physician's choice of the multikinase inhibitors (MKIs) cabozantinib or vandetanib as an... 
Via Benzinga
Could This 1 Problem Put a Dent in Novo Nordisk and Eli Lilly Stock?
Chasing indications for NASH has been a pitfall for many pharma companies. 
Via The Motley Fool
Gold Rush In Weight Loss Industry Impacts Retailers With Pharmacy Businesses
Retailers with pharmacy businesses, including major players like Walmart Inc (NYSE: WMT), Kroger Company (NYSE: KR), and Rite Aid Corp (NYSE: 
Via Benzinga
A $4,000 Investment in Bitcoin 10 Years Ago Would've Made You a Millionaire Today
The top crypto has had an astronomical rise. 
Via The Motley Fool
Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed
The Vanguard Value Index Fund ETF (ARCA: VTV) has beaten the Vanguard Growth Index Fund ETF (ARCA: VUG) by 5% during the past month. The momentum shift comes as investors recalibrate their strategies... 
Via Benzinga
Topics ETFs
5 Safe Stocks Under $40 to Buy Immediately
Investors are turning away from risky bets and putting their money in safe stocks this week. Here are four names under $40 to buy now. 
Via InvestorPlace
3 Fantastic Stocks to Buy in a New Bull Market
These stocks could be just the ticket if a sustained new bull market is beginning. 
Via The Motley Fool
Obesity Crisis Costs US $200B Annually, But Arrival Of Treatments Signal Declining Surgery Demands
With an annual toll of $200 billion due to health complications like diabetes and heart disease, the surging obesity crisis has adversely impacted Americans regarding health and the economy. However,... 
Via Benzinga
Topics Economy
Exposures Economy
Famed Weight Loss Drugs - Medications Far Pricier In US Than Other Developed Countries
A recent health policy organization KFF analysis highlighted that weight-loss drugs are considerably pricier in the U.S. 
Via Benzinga
'Bond Vigilantes Got It Right': Mark Chaikin Discusses Rising Yields, Key Stocks To Watch On Benzinga's PreMarket Prep
Via Benzinga
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
Eli Lilly and Company (LLY​​​​​​​) boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Fitch Flags Major Credit Risks Amid Sticky Inflation and High Interest Rates: Bond Market Turmoil Persists
Via Benzinga
Topics Economy
Exposures Interest Rates
3 of Eli Lilly's Top Drugs Grew by Over 40% in Q2. Trulicity Wasn't One of Them.
This already big healthcare business is about to get even bigger. 
Via The Motley Fool
Why This Nugget Of Bad Weight-Loss News Isn't Weighing On Lilly, Novo
Prescription trends data for July showed a slight decrease, but there's still room to run. 
Via Investor's Business Daily
7 A-Rated Biotech Stocks for Your August Buy List
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. 
Via InvestorPlace
Eli Lilly's Stock Spikes, Yet Team Jim Cramer Holds Back On Recommending Immediate Buying: 'Wait For A Pullback'
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.